Author: admin

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.

    To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 25 July (HL1340), what assessment they have made of the relative clinical benefits of the drug lenvatinib as opposed to sorafenib.

    Lord Prior of Brampton

    Ministers asked the National Institute for Health and Care Excellence (NICE) to develop technology appraisal guidance on the use of lenvatinb for the treatment of thyroid cancer on 22 July 2016. NICE plans to develop guidance on lenvatinib and sorafenib through the same technology appraisal and currently expects to publish draft guidance in October 2017.

    In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence and on the patient’s individual clinical circumstances.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.

    To ask Her Majesty’s Government on what date the Department of Health referred lenvatinib to NICE for a full technology appraisal.

    Lord Prior of Brampton

    Ministers asked the National Institute for Health and Care Excellence (NICE) to develop technology appraisal guidance on the use of lenvatinb for the treatment of thyroid cancer on 22 July 2016. NICE plans to develop guidance on lenvatinib and sorafenib through the same technology appraisal and currently expects to publish draft guidance in October 2017.

    In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence and on the patient’s individual clinical circumstances.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.

    To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 25 July (HL1340), what date has been agreed by NICE for a full technology appraisal of lenvatinib.

    Lord Prior of Brampton

    Ministers asked the National Institute for Health and Care Excellence (NICE) to develop technology appraisal guidance on the use of lenvatinb for the treatment of thyroid cancer on 22 July 2016. NICE plans to develop guidance on lenvatinib and sorafenib through the same technology appraisal and currently expects to publish draft guidance in October 2017.

    In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence and on the patient’s individual clinical circumstances.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.

    To ask Her Majesty’s Government when they expect lenvatinib to be available on the NHS for patients with radioiodine refractory differentiated thyroid cancer.

    Lord Prior of Brampton

    Ministers asked the National Institute for Health and Care Excellence (NICE) to develop technology appraisal guidance on the use of lenvatinb for the treatment of thyroid cancer on 22 July 2016. NICE plans to develop guidance on lenvatinib and sorafenib through the same technology appraisal and currently expects to publish draft guidance in October 2017.

    In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence and on the patient’s individual clinical circumstances.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.

    To ask Her Majesty’s Government what measures they intend to put in place to ensure that patients with radioiodine refractory differentiated thyroid cancer can receive all effective clinical treatments currently available through EU authorisation.

    Lord Prior of Brampton

    Changes to the process for evaluating cancer drugs were introduced at the end of July 2016 as part of the new arrangements for the Cancer Drugs Fund (CDF). Under the new arrangements, all new cancer drugs are expected to be referred to the National Institute for Health and Care Excellence (NICE) for evaluation through its technology appraisal programme. In some cases, NICE will recommend that the cancer drug is funded through the CDF, which enables further evaluation of its place in therapy. Drugs that have a European Union (EU) or United Kingdom marketing authorisation for radioiodine refractory differentiated thyroid cancer will therefore be reviewed under this process and if found to be clinically and cost effective will become established treatment within the National Health Service.

    The UK remains a member of the EU until Article 50 negotiations have concluded. EU law continues to apply and ongoing compliance with EU law is considered important in facilitating orderly transition, for negotiating purposes, and to offer certainty in the meantime. As long as the UK is subject to EU law, the present arrangements remain in place.

  • Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-09-05.

    To ask Her Majesty’s Government how many people are employed full-time and part-time by NHS England as (1) audiologists, (2) cardiac physiologists, (3) gastro-intestinal physiologists, (4) neurophysiologists, (5) respiratory physiologists, and (6) sleep physiologists.

    Lord Prior of Brampton

    NHS Digital collects data on the number of staff employed full-time and part-time by the National Health Service in England.

    Within the data held by NHS Digital it is not possible to definitively identify those staff groups requested. Therefore a best approximation has been provided based on the guidance available to NHS organisations. This information is in the attached table and provides the latest available data as at 31 May 2016.

  • Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-09-05.

    To ask Her Majesty’s Government how many patients were treated for hepatitis C and what were the actual or estimated costs of such treatment in each of the years 2014–15, 2015–16, and 2016–17.

    Lord Prior of Brampton

    Comprehensive data on all hepatitis C treatment in the United Kingdom is presented in the Public Health England annual report on Hepatitis C in the UK. The latest version published in July 2016 is called Hepatitis C in the UK 2016 report: Working towards its elimination as a major public health threat, and reported that treatment rates increased by around 40% in the calendar year 2015, up to 8,970 from an average of 6,400 in previous years. A copy of the report is attached. The report also presented preliminary figures to show that deaths in the UK from hepatitis C-related end stage liver disease and liver cancer fell for the first time in 2015, suggesting that access to new oral treatment via the early access schemes for patients with decompensated cirrhosis and cirrhosis may be having a positive impact.

    In April 2014, NHS England announced an interim commissioning policy to make these new highly effective oral treatments available to patients with liver failure. In June 2014, NHS England implemented a second Interim Commissioning Policy, extending access to patients with cirrhosis.

    Hepatitis C drugs are subject to commercially confidential discounts and rebate agreements. Releasing estimated or actual spend data includes the impact of these confidential prices which if released would inhibit the ability of companies to do business with the Department in the future. The Department has a duty to ensure that they adhere to the terms of confidentiality agreements when considering the release of information under the Pharmaceutical Price Regulation Scheme or other Commercial Medicines Unit drug framework agreements.

  • Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-09-05.

    To ask Her Majesty’s Government what assessment they have made of whether the additional £1.25 billion made available in the March 2015 budget for child and adolescent mental health services (1) was actually spent, and (2) was spent in addition to 2014–15 spending levels.

    Lord Prior of Brampton

    £143 million of additional funding was allocated in 2015-2016 for child and adolescent mental health services. Of this £143 million, £126.2 million was spent. The Government has committed to making available the full £1.25 billion announced in the March 2015 budget to transform children and young people’s mental health services over the lifetime of this Parliament. From 2016-2017, NHS England are establishing a baseline spend for specific programme areas such as children and young people’s mental health and will be able to track increase in spend on an annual basis.

  • Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-09-05.

    To ask Her Majesty’s Government what assessment they have made of whether the Basildon and Brentwood Clinical Commissioning Group has diverted finance intended for mental health services to reduce financial shortfalls in the acute sector.

    Lord Prior of Brampton

    No such assessment has been made. NHS England allocates funding to clinical commissioning groups (CCGs) to commission health services, including mental health services, to meet the needs of local communities. CCGs are responsible for decisions about how their allocation is used, taking account of local priorities, and are committed to increasing spending on mental health each year in line with the increases in overall National Health Service funding allocations. NHS England advises that, in line with Basildon and Brentwood CCG’s move towards parity of esteem, the CCG has increased investment into mental health services in 2016/17.

  • Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-09-05.

    To ask Her Majesty’s Government what assessment they have made of the reasons for the Basildon Clinical Commissioning Group spending less than the national average on mental health services, according to NHS Benchmarking figures.

    Lord Prior of Brampton

    No such assessment has been made by this Department. NHS England advises that the National Health Service benchmarking data for 2014/15 (the latest data available) shows that, compared to a demographically similar cluster of clinical commissioning groups (CCGs), Basildon and Brentwood CCG spends slightly more than the cluster average on mental health services (£13,499,988 per 100,000 population against £13,080,187) and is therefore not considered an outlier. This analysis of the benchmarking data is used because within the CCG cluster the prevalence of mental health conditions, and therefore the appropriate spending, is likely to be comparable.